Drug Approval | May 25, 2026
Datroway wins US nod in aggressive breast cancer subtype
Clearance marks major shift beyond chemotherapy
Clearance marks major shift beyond chemotherapy
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Clears major obesity endpoints at 80 weeks
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The approval was granted by Agenzia Italiana del Farmaco
Subscribe To Our Newsletter & Stay Updated
